ADmit Therapeutics

It's here!! The week when Barcelona becomes the center of attention for digital technology, innovation, and entrepreneurship. In this 11th edition of #4YFN MWC, I'll be moderating a session featuring 18 #health #spinoffs from the Catalan Bioregion, coming from the ecosystem of the Institut Català de la Salut and the Consorci de Salut i Social de Catalunya. On Wednesday 5th March at 3pm. At the end of the session, there will be a networking session at the Founders Zone (Hall 8.0) – Agora Side. The session will be part of the activities at the #Catalonia Health Innovation Ecosystem Pavilion (HALL 8.0 - 8.0C13), co-organized by Biocat, BioRegion of Catalonia, TIC Salut Social Foundation - Servei Català de la Salut and Barcelona City Council. Find the complete programme here: https://lnkd.in/dFmXYH4W List of spinoffs: myosafe, Biosfer Teslab, Trackyourmed, Health-Circuit, Bsure Medical, Time is Brain, tensormedical, Healthtech Innovations SL, Nema-Health, Tailor Surgery, Manina Medtech, AIMS-Medical SL, ARTIS Development, Predictheon, Swan Medical, ADmit Therapeutics, Ephion Health, NIMBLE Diagnostics. Many thanks to the organizers for the opportunity and to all the participating spin-offs for sharing their experiences! I look forward to seeing you all as we celebrate the grand party of entrepreneurship together! Pere Duran, Josep M. Pomar Reynés, Francesc Iglesias, Francesc Xavier Cos Claramunt, MD, PhD, Msc, Macarena Herranz Itúrbide, Anna Aran, Antoni Gilabert Perramon, Jordi Jordà Compañó, Robert Fabregat Fuentes, Joan Guanyabens, Victor Barberà Aranda. 4YFN.

Happy International Day of Women and Girls in Science 2025! At ADmit Therapeutics, we are proud to celebrate the incredible women who are driving innovation in STEM, especially in our mission to revolutionize the prognosis of Alzheimer's disease. Their dedication and expertise are essential to our work!    #nevertoodifficult #ADmit #InternationalDayofWomenandGirlsinScience #Alzheimersdisease #WomenInSTEM #AlzheimersResearch #Innovation #dementiawareness #EUeic #horizoneu #HealthMoonshot #AlzMoonshot

ADmit is turning 7 years old today!!!, and we are more dedicated than ever to the fight against Alzheimer's disease. The efforts of the last few years are beginning to bear fruit, and we have achieved significant milestones that position us at a critical turning point towards a positive trend. 1) We have developed the first IVD in blood to predict progression to Alzheimer's Dementia in patients with Mild Cognitive Impairment, the MAP-AD Test, which is in the CE marking approval process. 2) Our laboratory has obtained the certificate of accreditation from the College of American Pathologists (CAP), becoming the first CAP-accredited lab in Spain. 3) We have extended the scope of our ISO13485 to manufacturers. 4) The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) has granted us the “Licencia Previa de Funcionamiento de Instalación de Productos Sanitarios”. 5) We were pleased to welcome Dr. Russell Swerdlow, the renowned expert in the field of "Alzheimer’s Disease Mitochondrial Cascade Hypotesis", as a new member of our SAB. 6) We joined the StartUp Health’s Alzheimer's Moonshot Community, becoming part of this amazing group of Health Transformers. 7) We have established a Business Development Unit within our company, streamlining our team with the incorporation of Miguel A. Viribay, and reinforcing our Board of Directors with the incorporation of Ferran Prat as a Chairman. Finally, we are pleased to announce our incorporation in Almirall's Innovation Hub, The Hive, throughout 2025. This strategic move is aimed at accelerating the professionalisation of our team and will contribute to the realisation of our vision to become a leading company in the field of diagnosing and prognosing of age-related diseases. With this update, we would like to take this opportunity to extend our best wishes to you for a very Merry Christmas and a Happy New Year 🎉 🎊 🎁 #Alzheimersdisease #dementiawareness #EUeic #horizoneu #ADmit #nevertoodifficult #HealthMoonshot #AlzMoonshot #TheHive #OpenInnovation

ADmit Therapeutics recibe la acreditación del College of American Pathologists (CAP)!!! #Alzheimersdisease #dementiawareness #EUeic #horizoneu #ADmit #nevertoodifficult #HealthMoonshot #AlzMoonshot

ADmit Therapeutics receives accreditation from the College of American Pathologists (CAP)!!!   #Alzheimersdisease #dementiawareness #EUeic #horizoneu #ADmit #nevertoodifficult #HealthMoonshot #AlzMoonshot

ADmit Therapeutics receives accreditation from the College of American Pathologists (CAP)!!!   #Alzheimersdisease #dementiawareness #EUeic #horizoneu #ADmit #nevertoodifficult #HealthMoonshot #AlzMoonshot

We were delighted to attend CTAD Clinical Trials on Alzheimer's Disease 2024 in Madrid last week. Many exciting advances in the field of biomarkers and Alzheimer's therapy! We continue to unite our efforts to predict the progression of Alzheimer's dementia through epigenetic regulation of mtDNA and clinical data at MCI stage using machine learning. Together, we are moving towards improved clinical trials, personalised medicine and a dignified life for Alzheimer's patients. Thank you to all who contributed with their knowledge and feedback! #CTAD24 #Alzheimersdisease #dementiawareness #EUeic #horizoneu #ADmit #nevertoodifficult #HealthMoonshot #AlzMoonshot

Job Offer: Bioinformatician Jr.

 We are thrilled to communicate that we will present our MAP-AD Test for the prognosis of progression from Mild Cognitive Impairment to Alzheimer Disease Dementia in the CTAD Clinical Trials on Alzheimer's Disease in Madrid from October 29 to November 1. Come along and join our CEO Marta Barrachina, our Head of Assay Development Marta Blanch Lozano and our BD Director Miguel A. Viribay. We´ll be grateful to be able to share our knowledge and experience and contribute to a better and more dignified future for Alzheimer's patients. See you next week!! Theme 14: Beyond Amyloid and Tau P063: Novel blood-based mitochondrial biomarkers for the prognosis of progression from mild cognitive impairment to Alzheimer's Disease Dementia From Tuesday October 29 3:00 pm to October 30 5:00 pm. #CTAD24 #Alzheimersdisease #dementiawareness #EUeic #horizoneu #ADmit #nevertoodifficult #HealthMoonshot #AlzMoonshot

#DíaMundialDelAlzheimer | Se estima que más de 900.000 personas en España padecen #demencia, siendo la causa más común el #alzhéimer, responsable de hasta el 70% de los casos. 💊 Pese a los esfuerzos y los enormes recursos dedicados al campo de la enfermedad de Alzheimer, actualmente no hay aprobado ningún tratamiento que cure esta patología. 🔬 La #biotecnología está detrás de todos y cada uno de los medicamentos que se ensayan y finalmente aprueban, por lo que su contribución es lo que ha permitido la mejora en tratamientos de estos últimos años, que analizamos en este reportaje de la mano del trabajo de dos de nuestros socios: Laminar Pharma y ADmit Therapeutics. ➡ Puedes leer el reportaje completo, aquí: https://lnkd.in/dht8c7Fm #SomosBiotecnología